Virgilia Soto-Abraham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Virgilia Soto-Abraham has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Bernardo Moguel-González
Departamento de Nefrología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico
4 shared publications - Enzo Vásquez-Jiménez
Hospital Juárez de México, Mexico City 07760, Mexico
3 shared publications - Magdalena Madero
Department of Nephrology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico
3 shared publications - Alejandra Orozco-Guillén
Department of Nephrology, National Institute of Perinatology, Mexico City, Mexico
2 shared publications - Carlos Alfonso Guzmán-Martín
Doctorado en Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana, Mexico City 04960, Mexico
2 shared publications - César Flores-Gama
Departamento de Nefrología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico
2 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by Wolters Kluwer Health in Kidney360
Renal Trajectories Across Histopathological Phenotypes in Treated HIV
Background: Despite widespread antiretroviral therapy (ART), kidney disease in people living with HIV remains clinically and biologically heterogeneous. Persistent immune imbalance—reflected by CD4/CD8 inversion—often coexists with virologic suppression, yet its relevance within biopsy-defined renal phenotypes is incompletely understood. We aimed to characterize clinicopathological phenotypes and longitudinal renal trajectories in treated people living with HIV using the KDIGO histopathological framework. Methods: We conducted a retrospective multicenter cohort study of PLWH undergoing native kidney biopsy in Mexico (2019–2025) with ≥6 months of follow-up. Biopsies were classified according to the KDIGO proposal. Renal trajectory was defined as >25% decline (progression), ≤25% change (stabilization), or >25% increase (improvement) in creatinine-based estimated glomerular filtration rate (eGFR). Immunologic parameters, histological chronicity indices, and kidney outcomes were analyzed descriptively. Results: Thirty-eight patients were included (87% men; median age 43 years). Late HIV diagnosis was frequent (47% with CD4+ <200 cells/µL). At biopsy, 92% were receiving ART; however, CD4/CD8 inversion persisted in 84% at baseline and 76% at follow-up despite significant CD4+ recovery (p<0.01). After a median follow-up of 15 [8-18] months, 24% developed kidney disease progression, whereas 76% showed stabilization or improvement. Baseline albuminuria was significantly higher among progressors (3,589 vs. 339 mg/g; p=0.01), while CD4/CD8 ratio was not associated with short-term progression. Immune complex disease presented earlier after HIV diagnosis and showed immunologic improvement (CD4+ p=0.01; CD4/CD8 p<0.01) with stable renal function. Podocytopathies exhibited greater structural chronicity, and tubulointerstitial disease was frequently associated with opportunistic infections, particularly disseminated mycobacterial disease. Conclusions: In treated HIV infection, renal disease follows phenotype-specific trajectories in the context of persistent immune imbalance despite viral suppression. Albuminuria, rather than systemic immune indices, identified patients at higher short-term risk of progression. Biopsy-guided classification identified distinct clinicopathological phenotypes with different renal trajectories and may support individualized HIV–nephrology care in resource-constrained settings.
- 24 August 2026
- Published by Wolters Kluwer Health in Kidney360
Open AccessRenal Trajectories Across Histopathological Phenotypes in Treated HIV
Background: Despite widespread antiretroviral therapy (ART), kidney disease in people living with HIV remains clinically and biologically heterogeneous. Persistent immune imbalance—reflected by CD4/CD8 inversion—often coexists with virologic suppression, yet its relevance within biopsy-defined renal phenotypes is incompletely understood. We aimed to characterize clinicopathological phenotypes and longitudinal renal trajectories in treated people living with HIV using the KDIGO histopathological framework. Methods: We conducted a retrospective multicenter cohort study of PLWH undergoing native kidney biopsy in Mexico (2019–2025) with ≥6 months of follow-up. Biopsies were classified according to the KDIGO proposal. Renal trajectory was defined as >25% decline (progression), ≤25% change (stabilization), or >25% increase (improvement) in creatinine-based estimated glomerular filtration rate (eGFR). Immunologic parameters, histological chronicity indices, and kidney outcomes were analyzed descriptively. Results: Thirty-eight patients were included (87% men; median age 43 years). Late HIV diagnosis was frequent (47% with CD4+ <200 cells/µL). At biopsy, 92% were receiving ART; however, CD4/CD8 inversion persisted in 84% at baseline and 76% at follow-up despite significant CD4+ recovery (p<0.01). After a median follow-up of 15 [8-18] months, 24% developed kidney disease progression, whereas 76% showed stabilization or improvement. Baseline albuminuria was significantly higher among progressors (3,589 vs. 339 mg/g; p=0.01), while CD4/CD8 ratio was not associated with short-term progression. Immune complex disease presented earlier after HIV diagnosis and showed immunologic improvement (CD4+ p=0.01; CD4/CD8 p<0.01) with stable renal function. Podocytopathies exhibited greater structural chronicity, and tubulointerstitial disease was frequently associated with opportunistic infections, particularly disseminated mycobacterial disease. Conclusions: In treated HIV infection, renal disease follows phenotype-specific trajectories in the context of persistent immune imbalance despite viral suppression. Albuminuria, rather than systemic immune indices, identified patients at higher short-term risk of progression. Biopsy-guided classification identified distinct clinicopathological phenotypes with different renal trajectories and may support individualized HIV–nephrology care in resource-constrained settings.
- Open Access
- 23 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (13) , 6011
Kidney Transplant Recipients with Acute Antibody-Mediated Rejection Show Altered Levels of Matrix Metalloproteinases and Their Inhibitors: Evaluation of Circulating MMP and TIMP Profiles
Antibody-mediated rejection (ABMR) remains a major cause of renal graft dysfunction and loss. The histological hallmark of antibody-mediated rejection is progressive tissue damage, in which extracellular matrix turnover plays an important role. This turnover is mainly regulated by matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). Recent studies suggest that MMP/TIMP imbalance may favor the progression of renal damage, inflammation, and fibrosis, but the utility of these molecules as a biomarker of antibody-mediated turnover has not been fully explored. We measured plasma MMP and TIMP levels by ELISA in 15 patients with antibody-mediated renal transplant rejection and 12 patients without rejection. There was a significant increase in MMP-1, MMP-2, and MMP-3 concentrations in the plasma of patients with rejection, directly correlating with the severity of different renal lesions. In contrast, TIMP-3 levels were elevated in patients without rejection, showing a negative correlation with the severity of histopathological lesions. The concentrations of these molecules demonstrated good diagnostic capacity for patients with rejection. Our results show that MMP-1, MMP-2, MMP-3, and TIMP-3 could be potential biomarkers of rejection.
- 23 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (13) , 6011
Open AccessKidney Transplant Recipients with Acute Antibody-Mediated Rejection Show Altered Levels of Matrix Metalloproteinases and Their Inhibitors: Evaluation of Circulating MMP and TIMP Profiles
Antibody-mediated rejection (ABMR) remains a major cause of renal graft dysfunction and loss. The histological hallmark of antibody-mediated rejection is progressive tissue damage, in which extracellular matrix turnover plays an important role. This turnover is mainly regulated by matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). Recent studies suggest that MMP/TIMP imbalance may favor the progression of renal damage, inflammation, and fibrosis, but the utility of these molecules as a biomarker of antibody-mediated turnover has not been fully explored. We measured plasma MMP and TIMP levels by ELISA in 15 patients with antibody-mediated renal transplant rejection and 12 patients without rejection. There was a significant increase in MMP-1, MMP-2, and MMP-3 concentrations in the plasma of patients with rejection, directly correlating with the severity of different renal lesions. In contrast, TIMP-3 levels were elevated in patients without rejection, showing a negative correlation with the severity of histopathological lesions. The concentrations of these molecules demonstrated good diagnostic capacity for patients with rejection. Our results show that MMP-1, MMP-2, MMP-3, and TIMP-3 could be potential biomarkers of rejection.
- Open Access
- 11 March 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (6) , 1600
Plasma miR-150-5p in Renal Transplant Recipients with Acute Antibody-Mediated Rejection
Background: Rejection continues to be the main cause of renal graft loss. Currently, the gold standard for diagnosis is an allograft biopsy; however, because it is time-consuming, costly, and invasive, the pursuit of novel biomarkers has gained interest. Variation in the expressions of miRNAs is currently considered a probable biomarker for the diagnosis of acute rejection. This study aimed to determine whether miR-150-5p in serum is related to microvascular damage in patients with acute antibody-mediated rejection (ABMR). Methods: A total of 27 patients who underwent renal transplantation (RT) with and without ABMR were included in the study. We performed the quantification of hsa-miR-150-5p, hsa-miR-155, hsa-miR-21, hsa-miR-126, and hsa-miR-1 in plasma by RT-qPCR. The expressions between the groups and their correlations with the histological characteristics of the patients with ABMR were also investigated. Results: miR-150-5p significantly increased in the plasma of patients with rejection (p < 0.05), and the changes in miR-150-5p were directly correlated with microvascular inflammation in the allograft biopsies. Clinical utility was determined by ROC analysis with an area under the curve of 0.873. Conclusions: Our results show that the patients with RT with ABMR exhibited increased expression of miR-150-5p compared to patients without rejection, which could have clinical consequences, as well as probable utility in the diagnosis of ABMR, and bioinformatics may help in unraveling the molecular mechanisms underlying ABMR conditions.
- 11 March 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (6) , 1600
Open AccessPlasma miR-150-5p in Renal Transplant Recipients with Acute Antibody-Mediated Rejection
Background: Rejection continues to be the main cause of renal graft loss. Currently, the gold standard for diagnosis is an allograft biopsy; however, because it is time-consuming, costly, and invasive, the pursuit of novel biomarkers has gained interest. Variation in the expressions of miRNAs is currently considered a probable biomarker for the diagnosis of acute rejection. This study aimed to determine whether miR-150-5p in serum is related to microvascular damage in patients with acute antibody-mediated rejection (ABMR). Methods: A total of 27 patients who underwent renal transplantation (RT) with and without ABMR were included in the study. We performed the quantification of hsa-miR-150-5p, hsa-miR-155, hsa-miR-21, hsa-miR-126, and hsa-miR-1 in plasma by RT-qPCR. The expressions between the groups and their correlations with the histological characteristics of the patients with ABMR were also investigated. Results: miR-150-5p significantly increased in the plasma of patients with rejection (p < 0.05), and the changes in miR-150-5p were directly correlated with microvascular inflammation in the allograft biopsies. Clinical utility was determined by ROC analysis with an area under the curve of 0.873. Conclusions: Our results show that the patients with RT with ABMR exhibited increased expression of miR-150-5p compared to patients without rejection, which could have clinical consequences, as well as probable utility in the diagnosis of ABMR, and bioinformatics may help in unraveling the molecular mechanisms underlying ABMR conditions.
- Open Access
- 4 March 2024
- Vol. 62 (2) , 1-7
[Dual kidney transplantation, report of a case and review of the literature].
Kidney transplant is the best replacement therapy for kidney function; However, donors are insufficient, so extended criteria donors (ECD) are needed, which, in well-selected recipients, provide better survival than being on dialysis. Dual kidney transplantation (DRT) should be offered to elderly patients with lower immunological risk and with a lower body mass index. DCE are considered donors who died due to stroke, ≥ 60 years old or aged between 50 and 59 years, with diabetes or previous hypertension, clinical proteinuria, estimated glomerular filtration rate (eGFR) between 30 and 60 mL/min, or Terminal serum creatinine > 2.5 mg/dL. 57-year-old male patient undergoing TRD of a 67-year-old DCE, with creatinine of 2 mg/dL at the time of extraction, without previous pathologies, with eGFR: 34 mL/min, KDPI: 92% , KDRI: 1.64, Remuzzi pre-implantation biopsy 5, with 14-hour cold ischemia. He was discharged on the eighth day with a creatinine of 1 mg/dL. At 45 months with creatinine of 0.9 mg/dL, and eGFR by CKD-EPI of 91 mL/min/ 1.73m2. TRD is an alternative for ECD grafts. The "old for old" strategy allows TRD in older recipients a better survival than being on replacement treatment. The correlation with the KDRI, KDPI scales and the preimplantation biopsy according to the Remuzzi score improves transplant results by discarding kidneys with severe histopathological alterations, this can help reduce the rate of discarding SCAD and kidneys.
- 4 March 2024
- Vol. 62 (2) , 1-7
Open Access[Dual kidney transplantation, report of a case and review of the literature].
Kidney transplant is the best replacement therapy for kidney function; However, donors are insufficient, so extended criteria donors (ECD) are needed, which, in well-selected recipients, provide better survival than being on dialysis. Dual kidney transplantation (DRT) should be offered to elderly patients with lower immunological risk and with a lower body mass index. DCE are considered donors who died due to stroke, ≥ 60 years old or aged between 50 and 59 years, with diabetes or previous hypertension, clinical proteinuria, estimated glomerular filtration rate (eGFR) between 30 and 60 mL/min, or Terminal serum creatinine > 2.5 mg/dL. 57-year-old male patient undergoing TRD of a 67-year-old DCE, with creatinine of 2 mg/dL at the time of extraction, without previous pathologies, with eGFR: 34 mL/min, KDPI: 92% , KDRI: 1.64, Remuzzi pre-implantation biopsy 5, with 14-hour cold ischemia. He was discharged on the eighth day with a creatinine of 1 mg/dL. At 45 months with creatinine of 0.9 mg/dL, and eGFR by CKD-EPI of 91 mL/min/ 1.73m2. TRD is an alternative for ECD grafts. The "old for old" strategy allows TRD in older recipients a better survival than being on replacement treatment. The correlation with the KDRI, KDPI scales and the preimplantation biopsy according to the Remuzzi score improves transplant results by discarding kidneys with severe histopathological alterations, this can help reduce the rate of discarding SCAD and kidneys.
- Open Access
- 27 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 1888
Podocytopathy Associated with IgA Nephropathy in Pregnancy: A Challenging Association
IgA nephropathy is the most common form of primary glomerulonephritis. While associations of IgA and other glomerular diseases have been described, the association of IgA nephropathy with “primary” podocytopathy is rare and has not been reported in pregnancy, due in part to the infrequent use of kidney biopsy during pregnancy, and a frequent overlap with preeclampsia. We report the case of a 33-year-old woman with normal kidney function, referred in the 14th gestational week of her second pregnancy, due to nephrotic proteinuria and macroscopic hematuria. The baby’s growth was normal. The patient reported episodes of macrohematuria one year previously. A kidney biopsy performed at 18 gestational weeks confirmed IgA nephropathy, associated with extensive podocyte damage. Treatment with steroids and tacrolimus led to remission of proteinuria and a healthy baby, adequate for gestational age, was delivered at 34 gestational weeks and 6 days (premature rupture of membranes). Six months after delivery, proteinuria was about 500 mg per day, with normal blood pressure and kidney function. This case highlights the importance of timely diagnosis in pregnancy and underlines that good maternal and fetal outcomes can be achieved with appropriate treatment, even in complex or severe cases.
- 27 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 1888
Open AccessPodocytopathy Associated with IgA Nephropathy in Pregnancy: A Challenging Association
IgA nephropathy is the most common form of primary glomerulonephritis. While associations of IgA and other glomerular diseases have been described, the association of IgA nephropathy with “primary” podocytopathy is rare and has not been reported in pregnancy, due in part to the infrequent use of kidney biopsy during pregnancy, and a frequent overlap with preeclampsia. We report the case of a 33-year-old woman with normal kidney function, referred in the 14th gestational week of her second pregnancy, due to nephrotic proteinuria and macroscopic hematuria. The baby’s growth was normal. The patient reported episodes of macrohematuria one year previously. A kidney biopsy performed at 18 gestational weeks confirmed IgA nephropathy, associated with extensive podocyte damage. Treatment with steroids and tacrolimus led to remission of proteinuria and a healthy baby, adequate for gestational age, was delivered at 34 gestational weeks and 6 days (premature rupture of membranes). Six months after delivery, proteinuria was about 500 mg per day, with normal blood pressure and kidney function. This case highlights the importance of timely diagnosis in pregnancy and underlines that good maternal and fetal outcomes can be achieved with appropriate treatment, even in complex or severe cases.
- Open Access
- 10 November 2022
- Published by MDPI AG in Kidney and Dialysis
- Vol. 2 (4) , 588-594
An Unusual Cause of Acute Kidney Injury in Pregnancy: Beware of HELLP Look-Alikes
The differential diagnosis between new occurrence or revelation of chronic kidney diseases in pregnancy and hypertensive disorders of pregnancy is not easy, and the presence of a hypertensive disorder superimposed on a glomerular disease is even more challenging, as this case exemplifies. A 29-year-old woman was referred with HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome at the end of her pregnancy. Immediately after cesarean delivery, she developed anuria, unexplained by blood loss or hypotension, and in the absence of known nephrotoxic drugs. While the laboratory features of HELLP rapidly resolved, AKI persisted, and the finding of high-level proteinuria was the hint leading to diagnosis of a glomerular disease (focal segmental glomerulosclerosis, FSGS), later proven by kidney biopsy. This case, reporting on the rare association between HELLP and FSGS, offers the opportunity to discuss the role of proteinuria, hypertension, and in the differential diagnosis of pregnancy-related acute kidney injury (pAKI).
- 10 November 2022
- Published by MDPI AG in Kidney and Dialysis
- Vol. 2 (4) , 588-594
Open AccessAn Unusual Cause of Acute Kidney Injury in Pregnancy: Beware of HELLP Look-Alikes
The differential diagnosis between new occurrence or revelation of chronic kidney diseases in pregnancy and hypertensive disorders of pregnancy is not easy, and the presence of a hypertensive disorder superimposed on a glomerular disease is even more challenging, as this case exemplifies. A 29-year-old woman was referred with HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome at the end of her pregnancy. Immediately after cesarean delivery, she developed anuria, unexplained by blood loss or hypotension, and in the absence of known nephrotoxic drugs. While the laboratory features of HELLP rapidly resolved, AKI persisted, and the finding of high-level proteinuria was the hint leading to diagnosis of a glomerular disease (focal segmental glomerulosclerosis, FSGS), later proven by kidney biopsy. This case, reporting on the rare association between HELLP and FSGS, offers the opportunity to discuss the role of proteinuria, hypertension, and in the differential diagnosis of pregnancy-related acute kidney injury (pAKI).
- 20 July 2022
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 35 (9) , 2373-2375
Association between kidney biopsy findings in CKD patients with diabetes and renal replacement therapy initiation, a perspective from a low-middle income country
Kidney disease in diabetes mellitus is usually explained by diabetic kidney disease, but other superimposed etiologies occur frequently. The distinction between diabetic kidney disease and non-diabetic kidney disease can only be made by performing kidney biopsy. Our objective was to evaluate the association of diabetic kidney disease, non-diabetic kidney disease, or both with renal replacement therapy initiation. This is a retrospective cohort that included patients with type 2 diabetes mellitus for whom a kidney biopsy was indicated. Subjects were followed-up for 5 years, until renal replacement therapy initiation or were lost to follow up. One hundred and forty-one patients were included, 53 (39%) had diabetic kidney disease, 13 (9%) had non-diabetic kidney disease and 75 (54%) had both. Ninety-four percent of the cohort initiated renal replacement therapy during the 5-year follow-up. Higher degree of fibrosis was associated with a trend towards higher risk of requiring renal replacement therapy. In addition, the combined diabetic kidney disease + non-diabetic kidney disease group was associated with higher need of renal replacement therapy initiation when compared to the diabetic kidney disease group.
- 20 July 2022
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 35 (9) , 2373-2375
Association between kidney biopsy findings in CKD patients with diabetes and renal replacement therapy initiation, a perspective from a low-middle income country
Kidney disease in diabetes mellitus is usually explained by diabetic kidney disease, but other superimposed etiologies occur frequently. The distinction between diabetic kidney disease and non-diabetic kidney disease can only be made by performing kidney biopsy. Our objective was to evaluate the association of diabetic kidney disease, non-diabetic kidney disease, or both with renal replacement therapy initiation. This is a retrospective cohort that included patients with type 2 diabetes mellitus for whom a kidney biopsy was indicated. Subjects were followed-up for 5 years, until renal replacement therapy initiation or were lost to follow up. One hundred and forty-one patients were included, 53 (39%) had diabetic kidney disease, 13 (9%) had non-diabetic kidney disease and 75 (54%) had both. Ninety-four percent of the cohort initiated renal replacement therapy during the 5-year follow-up. Higher degree of fibrosis was associated with a trend towards higher risk of requiring renal replacement therapy. In addition, the combined diabetic kidney disease + non-diabetic kidney disease group was associated with higher need of renal replacement therapy initiation when compared to the diabetic kidney disease group.
- 17 November 2021
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 35 (1) , 367-369
Risk of acute rejection in kidney transplant recipients after COVID-19
- 17 November 2021
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 35 (1) , 367-369
Risk of acute rejection in kidney transplant recipients after COVID-19
- 8 May 2021
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 16 (5) , 685-693
Association between Postmortem Kidney Biopsy Findings and Acute Kidney Injury from Patients with SARS-CoV-2 (COVID-19)
Background and objectives: AKI in coronavirus disease 2019 (COVID-19) is associated with higher morbidity and mortality. The objective of this study was to identify the kidney histopathologic characteristics of deceased patients with diagnosis of COVID-19 and evaluate the association between biopsy findings and clinical variables, including AKI severity. Design, setting, participants, & measurements: Our multicenter, observational study of deceased patients with COVID-19 in three third-level centers in Mexico City evaluated postmortem kidney biopsy by light and electron microscopy analysis in all cases. Descriptive and association statistics were performed between the clinical and histologic variables. Results: A total of 85 patients were included. Median age was 57 (49–66) years, 69% were men, body mass index was 29 (26–35) kg/m2, 51% had history of diabetes, 46% had history of hypertension, 98% received anticoagulation, 66% were on steroids, and 35% received at least one potential nephrotoxic medication. Severe AKI was present in 54% of patients. Biopsy findings included FSGS in 29%, diabetic nephropathy in 27%, and arteriosclerosis in 81%. Acute tubular injury grades 2–3 were observed in 49%. Histopathologic characteristics were not associated with severe AKI; however, pigment casts on the biopsy were associated with significantly lower probability of kidney function recovery (odds ratio, 0.07; 95% confidence interval, 0.01 to 0.77). The use of aminoglycosides/colistin, levels of C-reactive protein and serum albumin, previous use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, antivirals, nonsteroid anti-inflammatory drugs, and anticoagulants were associated with specific histopathologic findings. Conclusions: A high prevalence of chronic comorbidities was found on kidney biopsies. Nonrecovery from severe AKI was associated with the presence of pigmented casts. Inflammatory markers and medications were associated with specific histopathologic findings in patients dying from COVID-19.
- 8 May 2021
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 16 (5) , 685-693
Association between Postmortem Kidney Biopsy Findings and Acute Kidney Injury from Patients with SARS-CoV-2 (COVID-19)
Background and objectives: AKI in coronavirus disease 2019 (COVID-19) is associated with higher morbidity and mortality. The objective of this study was to identify the kidney histopathologic characteristics of deceased patients with diagnosis of COVID-19 and evaluate the association between biopsy findings and clinical variables, including AKI severity. Design, setting, participants, & measurements: Our multicenter, observational study of deceased patients with COVID-19 in three third-level centers in Mexico City evaluated postmortem kidney biopsy by light and electron microscopy analysis in all cases. Descriptive and association statistics were performed between the clinical and histologic variables. Results: A total of 85 patients were included. Median age was 57 (49–66) years, 69% were men, body mass index was 29 (26–35) kg/m2, 51% had history of diabetes, 46% had history of hypertension, 98% received anticoagulation, 66% were on steroids, and 35% received at least one potential nephrotoxic medication. Severe AKI was present in 54% of patients. Biopsy findings included FSGS in 29%, diabetic nephropathy in 27%, and arteriosclerosis in 81%. Acute tubular injury grades 2–3 were observed in 49%. Histopathologic characteristics were not associated with severe AKI; however, pigment casts on the biopsy were associated with significantly lower probability of kidney function recovery (odds ratio, 0.07; 95% confidence interval, 0.01 to 0.77). The use of aminoglycosides/colistin, levels of C-reactive protein and serum albumin, previous use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, antivirals, nonsteroid anti-inflammatory drugs, and anticoagulants were associated with specific histopathologic findings. Conclusions: A high prevalence of chronic comorbidities was found on kidney biopsies. Nonrecovery from severe AKI was associated with the presence of pigmented casts. Inflammatory markers and medications were associated with specific histopathologic findings in patients dying from COVID-19.
- Open Access
- 22 July 2014
- Published by S. Karger AG in Nephron Extra
- Vol. 4 (2) , 119-126
Renal AA Amyloidosis in Patients with Type 2 Diabetes Mellitus
Background: Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease and a major cause of cardiovascular disease (CVD) mortality. Inflammation is closely involved in the pathogenesis of T2DM, and reactive amyloidosis occurs in the presence of chronic inflammation. We hypothesized that patients with T2DM may have a higher prevalence of renal AA amyloidosis (RAAA) and that this could contribute to worse atherosclerosis and CVD. Materials and Methods: We analyzed 330 autopsy kidneys from patients with a previous T2DM diagnosis. The kidney tissue was evaluated in order to determine the presence of diabetic nephropathy and RAAA, and systemic vessels were evaluated for the presence of atherosclerosis. Results: RAAA was detected in 9% of our study population and was associated with an increased risk for nodular sclerosis [OR (95% CI)] [11 (2.04-59.16)], for chronic ischemic cardiomyopathy [4.59 (2.02-10.42)], for myocardial infarction [3.41 (1.52-7.64)] as well as for aortic [4.75 (1.09-20.69)], coronary [3.22 (1.47-7.04)], and intrarenal atherosclerosis [3.84 (1.46-10.09)]. Conclusions: RAAA is prevalent in T2DM and is associated with worse CVD and renal disease, likely because RAAA is a marker of severe chronic inflammation.
- 22 July 2014
- Published by S. Karger AG in Nephron Extra
- Vol. 4 (2) , 119-126
Open AccessRenal AA Amyloidosis in Patients with Type 2 Diabetes Mellitus
Background: Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease and a major cause of cardiovascular disease (CVD) mortality. Inflammation is closely involved in the pathogenesis of T2DM, and reactive amyloidosis occurs in the presence of chronic inflammation. We hypothesized that patients with T2DM may have a higher prevalence of renal AA amyloidosis (RAAA) and that this could contribute to worse atherosclerosis and CVD. Materials and Methods: We analyzed 330 autopsy kidneys from patients with a previous T2DM diagnosis. The kidney tissue was evaluated in order to determine the presence of diabetic nephropathy and RAAA, and systemic vessels were evaluated for the presence of atherosclerosis. Results: RAAA was detected in 9% of our study population and was associated with an increased risk for nodular sclerosis [OR (95% CI)] [11 (2.04-59.16)], for chronic ischemic cardiomyopathy [4.59 (2.02-10.42)], for myocardial infarction [3.41 (1.52-7.64)] as well as for aortic [4.75 (1.09-20.69)], coronary [3.22 (1.47-7.04)], and intrarenal atherosclerosis [3.84 (1.46-10.09)]. Conclusions: RAAA is prevalent in T2DM and is associated with worse CVD and renal disease, likely because RAAA is a marker of severe chronic inflammation.